252131 Clinical Feasibility and Acceptability of PrEP Use among HIV-Uninfected MSM Who Seek Prevention Services at LGBT Community Healthcare Centers

Tuesday, November 1, 2011: 2:50 PM

Richard Elion, MD , Whitman-Walker Health, Washignton, DC
     
Results of iPrEX trial were published in the New England Journal of Medicine in November 2010. Briefly, there was a significant reduction of HIV infection, which increased with higher adherence rates among study subjects who received the active drug compared to those who received the placebo. Based on these findings, the CDC published interim guidelines for PrEP use among MSM in the January 28, 2011 issue of MMWR.

Learning Areas:
Protection of the public in relation to communicable diseases including prevention or control

Learning Objectives:
Describe and discuss the clinical feasibility and acceptability of PrEP use among HIV-uninfected MSM who seek prevention services at LGBT community healthcare centers.

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am Director of Research, Clinical Investigation at Whitman Walker Health. Responsible for the Role out of all research studies at Whitman Walker Health.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

See more of: HIV Pre-Exposure Prophylaxis (PrEP) for the Prevention of HIV Transmission among Men Who Have Sex with Men (MSM)
See more of: HIV/AIDS